BD advances efforts to combat antimicrobial resistance with enhanced diagnostic solution offering

Current trends project antimicrobial resistance could cause up to 10 million deaths annually by 2050. Fast and accurate identification of pathogens is often the first step in addressing this issue and with a complete and seamless identification/ antimicrobial susceptibility (ID/AST) solution, BD reinforces its commitment to support hospitals and researchers globally in managing antimicrobial resistance.

By directly offering MBT Biotargets and MBT Sepsityper, as well as standard reagents and other products, BD completes a comprehensive mass spectrometry solutions suite. MBT Biotargets are disposable plates that can be run multiple times, reducing waste. MBT Sepsityper, a new sepsis management kit, enables pathogen identification from positive blood cultures, eliminating the time-consuming step of culturing the micro-organisms.

"Comprehensive ID/AST solutions allow doctors and hospitals to diagnose and treat critically ill patients quickly and accurately," said Steve Conly, vice president and general manager of Microbiology for BD. "Our state-of-the-art ID/AST solution is just one way that BD helps to reduce the prevalence of antimicrobial resistance."

BD's complete portfolio offer of Maldi Biotyper products – including the MALDI Biotyper smart, an enhanced version of the BD Bruker Maldi Biotyper – allows health care providers to accurately and more effectively assist in diagnosing patients with infectious diseases in minutes. The seamless connectivity between the BD Bruker Maldi Biotyper, the recently launched BD Phoenix M50, and BD EpiCenter, a data management system, provide a comprehensive and efficient ID/AST solution for health care providers.

BD is a global medical technology company that is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. 

Bd advances efforts, combat antimicrobial resistance, enhanced diagnostic solution offering